med-tech valuat continu hold premium market
price-to-earnings basi pg head quarter gener dont
fundament concern backdrop especi given
favor y/i comp continu strong commentari
provid doctor limit currenc risk frankli
cautiou plethora issu underli tape fund
univers impact whole tape med-tech
fundament like last quarter littl room error around
coverag given multipl expect miss quarter
trade basi like neutral neutral
buy buy
would shi away edward ew neutral buy
varian neutral
util favor septemb tariff reportedli ad
anoth burden sector equat total impact
expect tariff china topic concern
neutral neutral may delv detail
potenti impact margin suppli chain
print like quarterli
trade run remain cheap face fairli easi comp
benefit neutral market price
face price pressur yet lead anoth beat
rais long term growth goal doubt front
less stellar result lastli expect anoth beat driven
philip phg rate strong hospit util
see risk around ew feel ew got
great run coapt sinc thv quarter hard predict
run creat risk consensu beat management may
may discuss pascal trial design feel still risk
cyno number get much focu still
like neg discuss china tariff
price target chang reason
pleas read import disclosur analyst certif appear appendix
tabl content
rel valuat multipl devic vs
preview forecast revenu adj ep
similar consensu think strong chanc deliv
upsid revenu given favor y/i comp hurrican last year
continu momentum high-growth area like tavr diabet
specif compani expect organ revenu growth
comp last quarter compani post revenu improv
comp reason believ util slow
feel momentum remain strong key portfolio tavr de
exce top-lin estim deliv clean margin think stock
work short-term beyond howev feel bump
tougher comp may continu trade rel discount
peer pathway toward mid-to-upp singl digit revenu
model organ growth toward higher end
manag guidanc quarter segment anticip
continu strength diabet minim ramp minim
intern market momentum guardian connect
stand-alon cgm market also support global result cvg
segment coronari structur heart sale still get boost
tavr larg part due evolut take share resolut onyx de
grew low respect rtg pain
therapi segment continu trend ahead expect intelli take
share player
quarterli call expect continu investor focu mitral
platform particularli heel tct whether might consid
bigger invest area mitral repair addit replac
await color newer product rollout aspir cathet
neurovascular side final follow pend acquisit mazor
mzor rate wed curiou chang long-term
segment growth expect increment appetit within
spine and/or ortho recent nass meet manag indic
estim spine market growth low-singl digit
select categori forecast heart failur con
cardiac vascular group con minim
invas group legaci covidien con spine
con restor therapi group con
diabet con
model chang correct spine estim felt prior
spine forecast low light improv seen
commentari made nass around joint capabl mazor
valuat rate neutral next twelv month price-to-earnings
basi share trade estim discount
large-cap med-tech peer group howev feel current valuat
warrant given slower growth vs group btig provid price
target neutral-r stock risk includ beat guidanc
oper margin expans underli pressur spine market
soft emerg market margin degrad expans
new busi line competit slippag product timelin chang
procedur reimburs futur devic data fda use
cash/m possibl multipl expans
bpsc growth bpsadj net bpsgross bpsebit bp btig estim compani filingsnewold changentm johnsonjnjund bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
medtron incom eproduct net y/i good gross total oper expens adj oper interest expens pre-tax incom adj net non-controlling adj net incom adjust ep share total net oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
preview forecast revenu adj ep
consensu revenu adj ep believ abt
earn risk quarter guidanc tightli control note co
guid seem littl impact currenc
fluctuat thu make f/x-relat adjust model
although revenu comp tougher particularli area like
establish pharma devic believ high-singl digit growth
remain achiev back continu out-performance diabet
diagnost penni two beat would surpris us share enjoy
nice run sinc result help favor intra-quart news well
success coapt trial result anticip fda approv label
expans mitraclip consequ posit
long-term revenu estim howev share trade
estim premium comp group feel much
optim reflect share
turn report segment establish pharma result solid last
quarter forecast moder mid-singl digit growth
given tough y/i comparison note india gst benefit skew result
within although anticip grow contribut
ellips mri-saf confirm ramp recogn tough replac
cycl headwind thu anticip flat y/i perform neuromod
model softer growth sequenti result salesforc chang
though expect fundament remain strong new aetna nation
coverag polici decis drg also support trend go forward
diagnost remain consist strong perform alin gain
traction europ diabet continu perform well buoy
libr sale increas reimburs ou final vascular expect
sequenti improv ramp xienc sierra stent though
uncertain stent competit vs mdt resolut
bsx synergi
segment model establish pharma revenu con
nutrit con diagnost con
devic con
call anticip continu investor focu mitraclip
late juli learn receiv approv enrol patient
summit trial evalu tendyn transap tmvr system
symptomat mr compar mdt intrepid studi seem inclus
criteria might cover sever fr would curiou hear
expect around enrol relat timelin diabet portfolio
remain hot topic investor look insight new
iter libr day approv real-tim alert europ
lastli curiou updat thought
model chang increas structur heart estim
expect success coapt trial lead fda approv symptomat
mr drive signific revenu ramp appli
higher-than-averag margin increment sale
valuat abbott rate neutral share appreci remark
year strong product launch remain posit abt base
busi see pathway drive mid-to-high singl digit growth
although mitraclip still modest portion busi
expect signific ramp label expans said share trade
premium comp group feel share rel valuat
appropri reflect risk vs reward btig provid price target
healthcar polici chang currenc fluctuat healthcar fall
favor fda regulatori agenc product delay failur execut
merger synergi
net ep gross bpsadj ebit bp btig estim compani filingsnewold changecagrntm johnsonjnjund fishertmobuy bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growthy/i growth oper adj aleretot y/i y/i growth y/i growth oper adj btig estim
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
preview quarter forecast revenu adj ep
procedur growth y/i consensu
estim revenu adj ep slightli
project procedur growth y/i model estim
system sold leas quarter consensu also expect
system consensu like model higher system procedur
intuit gotten larger quarter becom harder call
expect anoth procedur beat whether enough current
valuat idea
think investor grown somewhat accustom beat procedur
growth revenu sinc share trade past
coupl week strong result may help share trade-in demand
latest gener system like continu near term expect system
procedur growth exceed expect think small revenu beat
possibl hand stock trade ntm ep
weak either key metric especi procedur would like caus
forecast includ system revenu consensu
instrument revenu consensu servic revenu
con model y/i growth oper spend
full year top end y/i growth guidanc rang
beyond result procedur trend capital-expenditure purchas behavior expect
much discuss earn call focu isrg product pipelin
expect hear plan launch singl port da vinci
sp late earli system clear use
urolog procedur expect clear next transor procedur
manag hint toward measur roll-out hope hear
adopt expect futur procedur sp would ideal
system american colleg surgeri meet might nice spot
focu new system
earli septemb isrg flexibl robotic-assist cathet intend first
lung biopsi file fda investor like look detail
anticip regulatori timelin price commerci plan
beyond topic might includ impact clear
stapler bariatr surgeri procedur trend updat japanes center
adopt recent reimburs procedur news
impact trade tension china quota
model chang make chang model time
valuat rate neutral continu
out-performance like procedur trade ntm ep well
almost med tech btig provid price target neutral-
expect capit spend manipul futur competit
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
incom etot y/i sale oper interest incom tax non-controlling incom share adjust net adjust adjust net adjust oper expens ep btig estim compani report
enu eda vinci sale rest y/i asp asp realiz inc stock enu y/i vinci instal base da vinci da vinci da vinci da vinci instal y/i seq seq procedur procedures/instal enuetot world-wide y/i y/i singl y/i multisit singl blend report stock enu per stock enu instrument enu y/i enue/procedur inc y/i train enu instal base per train enu y/i enu y/i gross profit product product gross profit servic servic btig estim compani report
procedur eu procedur estim gyn dvh y/i y/i multi y/i singl y/i y/i y/i y/i y/i y/i dvp y/i y/i y/i y/i y/i surgeri includ ent cardiac vascular y/i y/i y/i y/i y/i y/i y/i y/i cardiac y/i y/i multi y/i singl y/i y/i surgeri inc y/i gener y/i y/i world-wide y/i seq btig estim compani report
procedur eou procedur estim y/i eu y/i y/i gastric y/i y/i eu y/i y/i y/i world-wide y/i seq btig estim compani report
buy pt
preview forecast revenu adj ep line
consensu face easier y/i comp vs
last year hurrican nice result could move share tad
respect procedur base commentari physicians/provid
seem core procedur stabl sequenti said
find littl risk meet estim disappoint given
bsx solid posit growth market formal clariti lotu edg
way expect less scrutini structur heart result though
expect continu momentum within acur eu launch acur
neo enhanc seal support trend watchman
neuromod growth impress expect above-averag
growth continu wavewrit ramp europ
forecast high-singl digit growth within med-surg fuel endochoic
spyglass endoscopi side stone franchis lithovu within
urolog segment feel mix bag result tough
comp pacer side reportedli low double-digit
call would interest addit color around recal
activ recent purchas three tuck-
in augmenix claret veniti articul plan fulli round
ownership stake milliped recent discuss around mitral
intensifi recent post tct would interest whether
might acquisit eye technolog within toolbox
specif product line model ww sale con
ww cv sale con ww endoscopi sale con
ww urolog sale con ww neuromod sale
con
model chang adjust long-term growth rate account
bullish structur heart peripher intervent estim lotu
edg ww eluvia incorpor slight dilut
acquisit announc augmenix veniti claret
milliped medic trim ebit margin estim slightli
oper net incom adj oper incom btig estim compani filingsnewold chang
valuat rate buy share trade ntm
estim price-to-earnings basi share valuat inch sinc high-
teen seen earlier year part due consist quarterli beat
grow optim around tavr portfolio though prefer chase
valuat also recogn multipl similar market-cap
weight basket compani grow revenu ep similarli view
bsx differenti product portfolio depend perform potenti
upsid recent support argument premium multipl
also lotu launch happen like appreci
stock momentum appli multipl month ep
estim deriv new price target
risk includ soft emerg market competit slippag
product timelin chang procedur risk tavr
reimburs futur devic data fda use cash/m
ntm johnsonjnjund bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
boston scientif incom enet y/i product gross research adjust oper incom one-tim interest pre-tax provis incom tax adjust net adjust ep share net oper pre-tax net product product product product tax tax growth adjust adjust pre-tax pre-tax adjust incom tax adjust net adjust tax btig estim compani report
boston scientif revenu edrug-elut y/i y/i heart y/i y/i y/i y/i y/i y/i y/i y/i y/i pelvic y/i y/i btig estim compani report neuromodul reclassifi segment electrophysiolog form rhythm neuro segment begin
preview model revenu line consensu ep
penni street note guidanc provid late juli
call revenu ep model
ww thv sale thv thv littl lower
consensu forecast thv thv
edward quarter alway imposs predict time
around approach quarter arguabl caution given increas
competit europ seem intensifi last quarter
earn solid run post-tct share afford miss
risk futur growth opinion
tavr expect center addit drive mid-teen growth
dont expect much benefit limit continu
access program japan adopt continu ramp annual
sale still expect double-digit growth europ
remain wildcard cautiou given competit price
non-tavr busi surmis upsid possibl
surgic valv segment inspiri resilia intuiti elit
beyond quarterli result expect keen focu tavr program
street look color whether pascal trial need
redesign either entir partial way random
mitraclip tct edward said plan review program also
curiou statu program like harpoon turn
cardioband continu monitor sale revenu recal
ew manag hope mitral sale cardioband
reportedli integr suppli chain risk
meet number hear physician procedur
lengthi complet topic would includ perspect
ncd tavr program though realist manag may comment
beyond alreadi said
model chang chang model time
valuat edward rate neutral feel ew current market
capit price lead market share fulli penetr
matur tavr market year feel share fairli valu
btig provid price target neutral-r stock risk includ
competit patent litig slippag product timelin chang
procedur reimburs futur devic data fda possibl
ntm johnsonjnjund bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i heart y/i heart y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i heart y/i heart y/i y/i non-gaap net y/i btig estim compani report
preview model revenu ep vs
consensu estim ep rang street ep
estim sure forecast account
excess tax benefit although estim assum
continu ramp procedur growth germani japan
built cushion typic summer slowdown perhap heavier
distract tct confer tct confer year took place
septemb vs octob given heavier normal news flow
observ strong presenc booth surmis
physician attend away procedur train
focu put year said demand around impella seem robust
miss would much surpris us whether compani beat
enough current share price harder predict margin tough
forecast typic challeng summer month
complic oper incom manag discret around time
hires/train expens though expect gross margin increas
conserv model similar level sg dollar spend
estim ebit margin
given run follow strong outcom data tct dont expect in-
line modest beat move share think investor expect meaning
beat current level posit updat japan pipelin
view two swing factor continu ramp japan rp roll-out
trend expect
call expect increment discuss heel tct
particularli around physician feedback color around new
smartassist technolog stemi dtu studi probabl wont
much clinic updat aha meet novemb expect
updat posit discuss closer aha reimburs
final ipp rate schedul kick octob chang all-
import drg posit drg biventricular open insert
remov drg icu care remov pump slate see
increas respect would curiou stabl
reimburs chang invest pci/shock program
model chang although still model conserv sg spend
ebit margin improv back half taken gross
margin reflect steadier cadenc improv throughout
year feel tad low estim adj ep vs
valuat rate neutral feel compani above-
averag revenu growth gross margin warrant premium multipl
peer share ntm revenu estim fewer near-
term catalyst move materi higher near-term think
share risk-reward roughli equal risk includ reimburs slippag
product timelin chang procedur patent litig futur devic
data fda possibl multipl expans
impella sale impella sale net incom btig estim compani model tax benefit go-forward basi estim may directli compar consensu forecast newold changentm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
preview fiscal fourth quarter model revenu
adjust ep vs consensu total
revenu estim near top end guidanc
rang includ diagnost consensu
breast health con medic aesthet con
gyn surgic con skelet health con
reduc medic aesthet sale estim reflect
compani voluntari suspens tempsur vitalia also trim
estim busi line fiscal year sinc dont
timelin associ fda scrutini make
conserv assumpt product famili reintroduc
time frame
share recov much loss
expect cyno medic aesthet sale result impact stock price
think in-line aesthet revenu result clariti outlook
divis need keep share current level feel anoth
miss possibl aesthet matter much investor
small part whole compani simpli key area
addit guidanc anticip quarter report
view street may look low-to-mid singl digit revenu
growth full year
add acquisit close octob
model increas breast sale estim
add revenu forecast
model alreadi includ impact faxitron bioptic purchas late
look beyond quarterli result expect discuss cfo
transit relat impact posit uspstf recommend
cervic cancer screen progress stabil novasur sale declin
health core breast health diagnost segment
told expect share trade time ep growth
multipl still see cynosur risk time
model chang lower sale estim medic aesthet
divis account suspens tempsur vitalia product line
forecast assum return product horizon
model also updat model focal therapeut
acquisit ad sale
forecast account cash transact
model revenu adj ep
revenu adj ep revenu
adj ep
valuat rate buy maintain pt reduc
valuat multipl prior month adjust ep estim
account prolong cyno turnaround use multipl
comp group reflect compani slightli lower revenu growth
investor sentiment take time turn risk includ cyno
result adopt chang reimburs diagnost price
slowdown novasur competit success integr
cyno
revenu incom btig estim compani filingsnewold changentm entm eepsrevsdentsplyxraynot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
holog incom million except total y/i sell gener oper interest incom incom tax incom share net calendar loss oper btig estim compani report
holog revenu million except selenia dffm asp y/i selenia tomo asp y/i tomo instal y/i breast imag revenu system y/i breast imag y/i imag y/i breast y/i y/i breast y/i breast revenu y/i breast revenu y/i y/i y/i y/i diagnost y/i y/i y/i y/i gyn surgic y/i skelet y/i y/i y/i y/i aesthet revenu y/i y/i revenu y/i btig estim compani report
preview would surpris anoth beat
third quarter though dont think like blow-out perform
seen second quarter given rais guidanc bar forecast includ
sale non-gaap loss per share consensu model
non-gaap lp result exceed would
surpris us seem get volum advertis price
long term expect price revers compet
close abt libr realli happen yet sale
estim assum y/i growth rate line assumpt full
year sale growth first full quarter launch estim
may conserv clear us much share
last quarter sale guidanc lift estim line
guidanc consensu look expect strong
quarter bar massiv beat unsur whether guidanc
taken higher may depend larg manag sens
environ time potenti price pressur tough determin
price might becom bigger issu hundr long term
payor contract negoti impact like gradual
share pull back last coupl week stock
trade beat level though strong quarter hint
increas price concern could lift share higher think mani investor
start scan horizon possibl turn point price expect
topic price next year becom stick point
bear
expect discuss earn call center launch
competit recent ce mark abt freestyl libr evolut
consum medic technolog glucos monitor space
signific dxcm recent purchas
model chang make chang model
valuat rate neutral believ current multipl
estim ntm ev/sal expens given potenti price
pressur face increas competit valuat seem
support investor concern competit price
like immedi and/or increas spend expect
exceed revenu estim wonder happen price
risk includ competit increas spend chang revenu growth
rate fda product recal reimburs price pressur
ntm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr profitev/salescagrcompanytickerr ptpricemarket cap
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
preview note varian report fiscal fourth quarter market
close octob hold investor event american societi
radiat oncolog astro annual meet morn
expect major new product releas meet new divis
presid helm oncolog system busi hope gain
insight var product pipelin focu futur also hope
better understand reason behind divis head chang
varian fiscal fourth quarter model gross oncolog order
y/i line street estim y/i typic
gross order matter investor sentiment swing unpredict
quarter quarter share trade past quarter
still trade premium price-to-earnings multipl larg cap med-tech name
believ in-lin gross order result need keep share steadi
howev saw updat impact tariff var
busi could outweigh import gross order result quarter
could risk expect question
model call revenu y/i street
estim y/i non-gaap ep line model vs
street forecast includ proton revenu line
street estim
full fiscal year street model within guidanc
estim gross oncolog order y/i total revenu
y/i non-gaap ep street forecast
gross oncolog order y/i total revenu
y/i non-gaap ep
expect issu guidanc includ rang revenu
growth non-gaap oper earn margin non-gaap ep
forecast anticip total revenu y/i non-gaap
oper earn margin non-gaap ep street
estim total revenu y/i non-gaap oper earn
margin non-gaap ep note outlook
oncolog revenu lower street estim may
conserv forecast revenu convers rate move part
order strength tariff impact leav room also
think guidanc could bracket street unless management feel tariff could
signific impact order convers look forward hear
call see risk
last quarter manag call possibl tariff could impact
gross margin sinc updat potenti implic tariff
look increasingli grim view accord compani latest
file addit us tariff list may less impact first
list second chines tariff list expect impact var export
china await discuss exactli could mean var gross
margin sale suppli chain outlook well updat discuss
us administr
earli august varian pick humediq global gmbh privat radiat
therapi compani focus patient posit identif motion
manag dont expect acquisit impact model
outlook transact seem signal manag continu interest
broaden radiat oncolog busi small deal rather
larg transform acquisit new type radiat oncolog
model chang make chang model time
valuat varian rate neutral feel current valuat
ntm ep estim fair expens varian slight premium
multipl compani similar growth btig assign price target
neutral-r stock risk includ halcyon adopt chang oper
margin capit spend slowdown hospit govern new
competit healthcar multipl gener trade lumpi quarterli
ntm johnsonjnjund bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discontinu non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
preview forecast revenu lp
comparison consensu estim call revenu lp
model complet cologuard test vs compani guidanc
consensu test recal result hurt
regrett chang compani messag potenti bill
paitent randomli weak june opportun meet
manag shortli compani comment
juli trend specif sens comfort new
messag benefit on-board rep would drive sale
feel doctor order pattern may take time also built
cushion around fact kit return unusu low late thu
estim could lower consensu feel unlik
miss guidanc even beat would surpris us told result
becom volatil share continu bounc hard
say exactli size beat would need move share higher
feel clearli enlarg share climb probabl
room small beat share feel miss guidanc
would punish long term see core hold feel
much visibl whether new messag drive sizabl beat
within month
call expect addit color rate
contract step compani taken alreadi look
updat progress recent salesforc hire market compani
also begun experi tv advertis physician wait
room look color pilot program doctor
educ effort respect label expans manag note
plan work fda would interest movement
competit landscap alway remain topic interest
american colleg gastroenterolog acg meet octob learn
earli data competit blood test lastli look
increment discuss develop effort toward liver lung
cours one long-term initi garner plenti attent penetr
hospit system thu would expect discuss outreach effort
improv electron order
model chang chang model
valuat rate buy pt base dcf
risk includ cologuard adopt execut co-promot
agreement unsuccess expans younger patient increas spend
competit data new product guidelin chang chang
discuss chang obamacar chang reimburs
addit delay poor data lung test need
capit difficulti hire salespeopl creat strong advertis high-
multipl healthcar stock fall favor
exact scienc incom million usd except per-shar etot profit relat y/i profit research gener sale interest expens incom incom incom ep share analysi revenu good profit product revenu ex net incom tax incom net incom btig estim compani report
exact scienc revenu million enumb order sequenti new physician adopt assumptionsnew physician order tests/new complianc test new reorder rate assumptionsreord order tests/reord complianc test reorder cologuard test growth tests/ord testsscreen opportun penetr rate annual volum tradit volum medicar volum volum tradit medicar reimburs reimburs medicar reimburs medicar laboratori servic accrual revenu revenue-per-test ex- btig estim compani report
buy pt pt tbd
preview third quarter estim revenu
ep vs consensu feel beat like
philip combo continu ramp total sale forecast includ
rainbow consensu expect project y/i growth
product revenu includ royalti quarter consensu
expect y/i growth see strong growth stori
trade ntm ep move multipl get
new pt
guidanc target total revenu product revenu
ep model slightli total sale
product revenu y/i growth ep
y/i growth ep feel may move higher
saw last quarter believ sever factor drive masi
revenu growth expect compani post revenu beat
nudg guidanc manag conserv approach toward guidanc
well on-going catalyst philip partnership impress growth
newer measur multi-year contract intern adopt
trend give us confid strong report
share recent pull back all-tim high although think
stock could move higher quarterli beat investor may want someth
meatierlik discuss pipelin major new product
expect one rel soon though dont know time trackabl metric
benefit phg relationship commit near-term
acceler stock repurchaseto move stock back higher
model chang make chang model
valuat rate buy rais price target
use multipl month non-gaap ep forecast
trade non-gaap ep estim choos use
multipl believ compani strong growth profil philip partnership
fast cadenc product innov warrant valuat multipl
comp group compar compani fast-grow product
revenu note optic masi total revenu growth rate
impact royalti roll year view reason
comp tabl includ profit med-tech compani similar revenu
adopt margin advers impact relationship philip
ntm medicalgmedneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/sal
masimo incom eproduct y/i y/i y/i good gross litig award defens costs- total oper oper incom non-oper pre-tax incom tax non-control interest net share total non- adjustments- non- net adjust ep marginsgross gross net total total total oper ep ep ep ex royalti btig estim compani file adj ep includ adjust due fx
masimo revenu eglob instal base instal base new unit y/i unit annual retir instal base y/i new unit rainbow monitor total instal busi averag instal base averag y/i sensor asp estimate sensor respiratori set y/i total product busi asp y/i rainbow y/i rainbow average rb instal base average y/i rainbow sensor asp estimate sensor y/i total product sphb y/i product y/i y/i net y/i btig estim compani report
preview model revenu adj ep fairli
similar firstcal consensu model constant currenc growth
exclud tandem vs manag full year expect
full year currenc manag reiter prior expect
expect impact recent septemb dont expect mani
surpris overal see littl risk total top-lin forecast note
weather issu hurt neuromod sale make favour
y/i comp perspect post revenu growth
think strong chanc could deliv
notabl comp turn difficult cycl sentiva
launch ramp hlm sale either way share reflect
consider optim ahead depress opportun feel
result stellar push stock higher point depress
approv signific progress caisson might type catalyst
would requir anoth meaning move upward
cardiopulmonari hlm sale continu benefit upgrad
replac exist devic competit gain turn
heart valv anticip double-digit growth percev howev
may linger pressur termin oem contract
hurt segment sale last quarter regard neuromod
anticip on-going sentiva adopt neuromod unit
ou momentum still buoy recent ce mark approv sentiva
well busi model chang japan
estim segment model cardiopulmonari sale con
heart valv sale con neuromod sale
call anticip commentari livn mitral portfolio
caisson prelud feasibl trial success conclud enrol
begun interlud ce mark trial notabl dr mathew william
nyu present tct impress caisson short mean
procedur time minut broadli curiou livn
appetit increment invest outsid highlif caisson possibl
transsept repair space expect discuss long-term
restore-lif trial sleep apnea final could
discuss ahead medicar decis treatment-resist depress
late novemb perhap around whether compani begin invest
ahead favor outcom lastli margin sens investor
commun pay closer attent recent increas sg
spend could risk share inflect point
model chang chang model time
valuat rate neutral price-to-earnings basi share trade
mani livn peer large-cap mid-cap grow revenu similar
place flip side share also trade smid cap name
feel grow faster long-term use target multipl line similar
smid cap grower would see hypothet price target
shade trade today think immedi accret
growth market could serv catalyst stock feel quit
bit good news price depress say could
big disappoint btig provid price target neutral-r
volum slow vn new patient growth competit issu fda
trials/develop unsuccess bid medicar coverag vn
ntm capjohnson johnsonjnjund bdxnot scientificbsxbuy cap capresmedrmdnot medicalwmginot cap factset data btig estimatespr ex-amortev/salescagrcompanytickr ptpricemarket cap
non-gaap incom growthnacost good sold oper incom continu incom continu minor tax expens net share oper pre-tax net net net net oper calcul effect tax calcul effect tax btig estim compani reportsfor quarter tax-effect earn use tax rate deriv ep comparison purpos
consolid million machin includ report cc report cc system report cc report cc report cc heart report cc heart valv includ sutureless report cc report cc report cc sorin btig estim compani note sub-seg within cardiopulmonari heart valv cardiac rhythm repres btig estim actual result attempt estim line item base histor provid sorin prior merger go-forward basi compani disclosur
consolid revenu million epilepsi marketestim new lead revenu gener revenu revenu new need implant assum yr receiv gener revenu lead gener neuromodul epilepsi marketestim new y/i lead revenu gener revenu revenu new need implant assum yr receiv gener revenu y/i ou lead ou gener ou neuromodul cc revenu legaci btig estim compani report
preview third quarter forecast total revenu
non-gaap ep consensu line us non-
gaap ep estim midpoint total
revenu guidanc rang expect meet beat
consensu estim manag signal confid
commentari recent investor confer re-affirmed guidanc
septemb believ inventori issu trip compani
resolv manag highlight
benefit go direct help result also believ room
inventori drag built guidanc quarter issu
resolv quarter look good meanwhil compani payor win
earlier year continu support strong omnipod sale growth
like sever rel high-multipl name share trim
gain past coupl week stock trade slightli
fast-grow med-tech comp group think fair given compani
strong growth competit increasingli crowd market believ
share could move higher top-line beat posit discuss
around european transit seem possibl said cant
entir rule inventori issu creep earli part
variou busi line forecast us omnipod sale
intern omnipod sale drug deliveri revenu
consensu far estim forecast us omnipod
sale intern omnipod sale drug deliveri
look guidanc call total revenu rang
model call full year total revenu includ
us omnipod sale intern omnipod sale
drug deliveri sale model gross margin full year
line guidanc howev jump gross margin came ahead
schedul would surpris see post higher margin
back half year forecast
besid intern sale model increas patient access us
earli feedback dash limit market releas expect manag
discuss howif allth ceo transit may impact podd prioriti
expect major shift strategi
model chang make chang model
valuat insulet rate neutral trade ntm revenu
forecast continu see benefit tubeless insulin pump
omnipod result exceed expect believ stock fairli
valu time btig provid price target neutral-r
stock risk includ disrupt intern revenu instal
patient base increas competit potenti prefer partnership
major insur group lack visibl next drug
deliveri product
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
incom statement adjust nd etot revenu y/i growth adjust neighborhood good oper expens tax expens net incom share net incom adjustments- gaap net incom gaap ep growth y/ymarginsgross incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens quarterli result growth rate adjust neighborhood divestituresourc btig estim compani report
revenu etot revenu omnipod y/i omnipod y/i deliveri y/i revenu exclud neighborhood y/i growth adjust neighborhood revenu omnipod revenu breakdownbegin instal new patient start patient y/i patient attrit instal instal base average es order per re-ord annual new user quarterli annual asp new patient revenu new user total omnipod y/i productivity/rep omnipod revenu breakdownbegin instal new patient patient y/i patient attrit instal instal base average es order per re-ord quarterli annual asp new user quarterli annual asp new patient new user total omnipod y/i deliveri revenuesymphoni health data forecast neulasta syring neulsasta onpro total neulasta y/i estim neulasta sale attribut onpro neulasta sale attribut onpro total neulasta onpro end-us neulasta onpro impli neulasta onpro total neulasta onpro total neulasta onpro revenu total neulasta onpro drug total report drug deliveri sourc btig estim compani report symphoni health solut symphoni health symphoni health b/c btig estim report drug deliveri revenu /f btig estim
preview model revenu lp line
consensu revenu better lp model flattish sequenti revenu
allow typic summer season well fact newer rep
expect product said expect
gener tone manag commentari remain bullish mirror
articul recent confer august septemb
small beat would surpris salesforc buildout manag
success fill plan headcount ahead schedul hint
could addit hire overal feel irtc model
remain competit well-posit consist beat throughout
year mani high-valu name pinpoint
one near-term catalyst would drive multipl expans though
feel street estim appropri conserv modest
insuffici beat may even put share risk given current level
call would interest zio adopt though
manag indic previous would provid limit color
product materi portion revenu addit curiou
ramp new rep whether manag might comment
headcount plan beyond intra-quart much attent
new ecg function appl watch buy analyst walt piecyk pt
whether might competit could question
around though curiou could work collabor
tech player back end final competit landscap alway
hot topic sens consider lead feel privat player
like bardydx privat rais fund recent may carv
like stori struggl share rel ev-to-sal valuat
ntm revenu estim irtc above-averag growth profil
warrant richer multipl vs peer group fast-grow med-tech name
also feel compani bump larger number competit
would comfort target multipl appli
forward estim yield enough upsid buy rate
model chang make chang model time
valuat irhythm corpor rate neutral remain posit
base busi worri competit long-term see irtc
current ntm ev-to-sal valuat vs fast-grow peer
group fair btig provid price target neutral-r stock
risk includ competit ip protect new market delay reach
profit medicar commerci reimburs abil recruit/retain
salespeopl unsuccess salesforc execut broad healthcar sector
ntm inc ingnnot inc beatnot factset data btig estim price ex-amortev/salescagrcompanytickerr ptpricemarket cap
irhythm incom million usd except per-shar research sale income/ loss incom share analysi revenu good net incom tax margin incom net incom btig estim compani report
irhythm revenu million zio xt growth growth restat y/i growth annual rep fte revenue-per-ft chang chang chang zio mct procedur rate penetr stream mix given client mix mix direct direct btig estim compani report
preview compani pre-announc revenu
forecast expect guidanc rais given ytd trend come
street expect call despit share dip
along recent share offer stock experienc nice run sinc
result dont expect earn alon serv much catalyst
consid compani also announc complet enrol
converg late august realist unless compani provid
bullish outlook beyond dont expect share move much
get closer data
analyst day held recent doubt much
updat strategi front key trial look updat
might see first data set converg whether updat
timelin final expect investor focu china result given volatil
though expect benefit recent distribut
agreement baheal privat
model chang updat revenu model pre-
announc addit increas share count assumpt
recent capit rais
valuat rate neutral ev-to-sal basi share
trade next twelv month estim though expect investor
interest heighten near data encourag
consist open surgeri result feel share fairli valu
consid compani revenu growth absenc materi catalyst
trial data releas said today world may see
valuat cheap would argu believ quarter
remain lumpi think stock could becom interest
near data btig provid price target neutral-r stock risk
includ trial data success physician train surgic procedur
salesforc product open-heart surgeri volum fda volatil
ou result share shift away surgic ablat procedur litig
revenu growth ebitda ep btig estim compani ebitda margin exclud stock-bas comp item newold chang
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
atricur incom research gener expens incom pre-tax incom tax net incom dilut ep share net incom tax expens incom amort compens adjust ebitda margin y/i chang analysi good research gener net incom tax btig estim compani report
statesest open-heart procedur open-heart ablat ablat mi procedur mi asp invas ablat atriclip procedur atriclip asp ablat tool unit open-heart procedur ou open-heart ablat ablat mi procedur ou mi ablat atriclip procedur ou atriclip ablat atriclip tool btig estim compani provid dollar revenu per segment procedur price detail present model estim base compani commentari
preview cautiou around earn report stock
move higher sinc last quarterli earn report
catalyst feel share level demand perfect although
expect compani continu strong sale perform would
surpris revenu beat feel someth rang would
need keep share steadi post run larger beat think
unlik could move share higher in-lin quarter
expect entir rule would probabl disappoint
current share price feel share like range-bound report
third quarter model sale flexitouch revenu growth
adj ep consensu forecast total revenu
adj ep
look full year continu forecast guidanc estim
total revenu flexitouch sale growth y/i view
tcmd revenu guidanc conserv expect
quarterli beat small guidanc rais
one key reason believ annual sale guidanc surpass intra-
quarter announc tcmd new feder suppli schedul contract
win addit new flexitouch contract new
contract give va patient access flexitouch technolog came
earlier expect went effect septemb tcmd sale
cadenc typic includ larger contribut commerci patient
patient often satisfi deduct point
year sale va patient make signific portion revenu
first quarter year va patient dont pay deduct new
contract place month ahead end year timelin
anticip think sale may particularli strong
sale result continu roll-out flexitouch flexitouch head
neck remain focu earn report also new
cfo consider experi med-tech field expect
signific chang near-term spend prioriti look reiter
compani strategi salesforc expans
model chang make signific chang model
correct prior cleric error calcul adj ebitda
enter credit agreement rate
earli august sinc compani yet borrow credit
facil unus line fee rate per year neglig
yet includ facil model
valuat rate neutral
current trade ntm revenu multipl small-cap
medic suppli comp group believ premium multipl
appropri given tcmd expir patent potenti competit
price pressur beat rais great valuat seem full
us
risk includ potenti increment share dilut lcd decis
competit expir patent technolog advanc reduc burden
lymphedema salesforc buildout market size estim vari doctor
opinion pcd stand-alon treatment
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
incom good gross total oper expens incom pre-tax incom tax adj net incom adj net incom loss ep dilut share net incom adjustments- net incom adj adj ebitda profit incom tax net oper btig estim
revenu revenu y/i revenu y/i revenu y/i revenu y/i forc histor quarterli headcount estim additionsregion headcountregion end revenue/rep quarter revenu end y/i btig estim compani sec file
preview earli octob announc preliminari revenu
line consensu estim
estim four senhanc system sold quarter one
us three emea one system one us two
emea system includ guidanc forecast worth note
one emea system use demo may explain
revenu lower might expect four system sale
system sale plu think investor hungri us
sale view extra emea system good second us
system quarter would better think investor look
momentum domest sale direct us senhanc launch near
one-year anniversari know investor patienc need take
quarter move earli discuss signatur contract still
think evid strong us adopt key catalyst need
acceler share stage
potenti stock catalyst forese formal earn report
look ahead system sale past compani given report
system sale alreadi complet quarter howev call
manag offer guidanc system sale unsur
treat discuss system sale quarter senhanc
quit visibl american colleg surgeri week boston
compani host physician investor event
revis model pre-announce revenu number
system sold also increas forecast number ou system sold
expect discuss compani recent announc mst
acquisit wrote septemb note plan includ
impact model deal close also recent announc
ce mark clearanc ultrason instrument system continu
anticip fda clearanc portfolio expans well
mm articul instrument help expand senhanc procedur
encourag adopt
model chang updat model reflect pre-announce revenu
fourth system sale third quarter announc earli octob
increas system forecast one ou system expect
sale us system ou system increas instal base
increas forecast instrument stock revenu outyear
addit correct cleric error ep calcul plan
add impact mst acquisit model transact
close like
valuat rate neutral valuat base dcf
btig provid price target neutral-r stock risk includ
servic need wrist instrument larger competitor litig
economi pressur capit spend reimburs need
system incom marginnmnmnmnmnmnmnmnmnmsourc btig estim compani filingsnewold chang
incom etot revenu y/i good intang chang fair oper incom interest incom tax expens net incom share net incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens btig estim compani report
revenu esenh salesu senhanc sale revenu row revenu total senhanc revenu senhanc instal baseu instal ins- senhanc instrument/stock revenuetot target market senhanc market procedur procedur total row target market senhanc row market row procedur row procedur senhanc world-wide procedur instrument asp total instrument revenu senhanc requir stock us- senhanc requir stock total senhanc requir stock asp total stock revenu total senhanc instrument stock revenu senhanc servic train revenu instal base per system servic train revenu total senhanc revenu revenu btig estim compani report
preview estim revenu vs consensu though
admit littl go time predict quarter
surprisingli given mani variabl around busi model consensu
rang fairli wide though around rang model
estim revenu ramp sale traction bear fruit
cours year report result consist short
forecast hard much confid uptak improv sinc
last quarter call manag conced difficulti
intern forecast manag plan re-evaluate guidanc along
result share hover close low think
investor expect guidanc lower probabl much risk
share go print limit expect time
point posit updat lrti test china opportun
expect better growth could lift fairli depress share though
littl confid occur
call interest hear success plan head
emea sale resign late septemb look updat
sale profit new rep per manag commentari new direct
sale rep came on-board last quarter addit await updat
statu regulatori trial sever bacteri pneumonia test kit
lastli keen updat chines market opportun base
manag commentari last earn call compani
plan initi process local trial registr
commerci establish foothold china
model chang chang model time
valuat rate neutral valuat dcf-
base use discount rate given string quarterli miss
last year on-going challeng within hospit purchas
environ see consider risk achiev estim btig
provid price target neutral-r stock risk compani
acquir meet estim lengthen adopt cycl lrti data
build salesforc ou expans competit chang
fda regul need capit retract healthcar stock
valuat hospit spend slowdown
incom million except ep elicens y/i oper expens incom tax incom share incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens incom nmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet oper loss btig estim compani report
placement/revenu eu capit equipmentinstru contract evalu cumul begin quarterli quarterli quarterli contract evalu cumul end instrument quarter addit reagent instrument asp instrument sold instrument revenu per day per activ per per activ y/i consum revenu revenu equipmentinstru contract evalu cumul begin quarterli quarterli quarterli contract evalu cumul end instrument quarter addit reagent instrument asp instrument sold instrument revenu per day per activ per per activ y/i consum revenu ou revenu equipmentact instrument quarter addit revenu per day per activ per activ consum revenu product revenu btig estim compani report
preview xent model revenu lp vs
street lp forecast bottom end
guidanc rang sale sinuva model
sale quarter follow lower guidanc last quarter street
expect sinuva sale like achiev level given revenu
segment guidanc product line set
bottom end rang assum small step
quarterw expect meet expect sinuva feel investor
would like see product ramp toward upper end
cautiou core busi propel sale suffer last
quarter attent requir sinuva launch model
sale core busi street addit
resourc dedic sinuva hope propel sale recov
believ show consist improv segment
next coupl quarter regain investor confid
quarter news insur coverag sinuva lift share
win larg payor clear posit dont expect overnight
improv patient access issu buy-and-bil requir
discuss earn call think launch may take coupl
quarter find foot think much investor discuss
call focu updat around item well potenti
question adopt ramp earli adopt physician view
competit therapi payor convers
beyond earn biggest upcom catalyst potenti
grant sinuva code novemb remain hesit declar
done deal say simpli know act believ
investor take reimburs win grant thu may
consider downsid novemb decis produc clean
product-specif code weve written see preliminari
non-coverag decis may mistak strong view
either way whether revers earlier decis longer term
see sever new product pharmaceut potenti compet
sinuva either surgeri lieu surgeri altogeth
model chang make chang model time
valuat intersect ent rate neutral intersect primarili valu
sale growth trade ntm ev/sal estim
comp group feel fair light reduc guidanc
complex around sinuva launch btig provid price
target neutral-r stock risk includ product access issu adopt
pushback futur competit advers event relat product
ntm medicalwmginot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptprice market cap
incom etot y/i sale oper incom incom tax expens incom share oper expens btig estim compani report
revenu etot propel/contour y/i propel/contour y/i y/i propel/contour q/q propel/contour q/q q/q per unit sold per unit sold per per unit sold sale rep etot distribut rep rep rep month rep btig estim compani report
buy pt pt tbd
preview model report revenu vs
consensu estim gross order look
assum approxim six mridian system
found reliabl consensu estim gross order metric order like
import
host investor event octob american societi
radiat oncolog meet san antonio expect focu
meet clinic center mridian system mr-guid
radiotherapi technolog expect discuss around competit
commerci earli stage system price adopt ramp barrier
adopt long-term strategi
earn call expect investor interest order funnel updat
tender live system use treatment time use
adapt plan associ reimburs capac addit
system instal convers system backlog cash burn
elekta ekta-b st rate sell ce-mark mr-linac
quarter wed like hear sell process chang
whether new entrant market impact order decis time
forecast revenu top end
guidanc rang consensu model gross
order full year continu expect quarterli lumpi
model chang adjust model secondari offer
mid-august increas share count share
impact price target lp estim
order order marginnmnmnmnmnmnmnmnmnmsourc btig estim compani filingsnewold chang
valuat rate buy reduc price target
previous reflect higher share count secondari
offer mid-august continu use ev/sal multipl
project month revenu multipl ntm revenu
multipl averag fast-grow not-yet-profit med-tech
comp group line current valu investor assign
risk includ competit order volum abil convert order revenu
system fall backlog mri rt adopt long-term clinic data
potenti dilut product delay reimburs
ntm inc ingnnot factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
incom product servic total y/i other- total cost gross sell gener total oper incom loss incom pre-tax incom incom taxes- net incom non-controlling net incom loss share marginsgross net oper expensenanananananananananananananananananananaep growthnanananananananananananananananananananasourc btig estim compani report
revenu egross y/i y/i y/i y/i y/i growthnanananananananananananananananananananatot y/i y/i unit product servic gmnanananananananananananananananananananatot total btig estim compani report
preview sinc commenc us launch august
think investor use quarter judg us traction go
expect us sale meaning ramp come
quarter forecast revenu lp compani
report consensu expect lp feel
consensu met model revenu lp
vs consensu expect guidanc set
may tad aggress light posit view
product see consensu year achiev
share recent sold without valid reason
strong quarterli call feel excel entri
point anyon couple-year horizon expect sale meaning
ramp partnership roch renew like earli next year
could sooner
kick launch polici coverag horizon cross
shield new jersey horizon healthcar new jersey compani
press releas addit payor win quarter
believ like make stride region insur may list
new polici and/or progress toward coverag discuss earn
call number live coverag updat could nice catalyst see
reimburs gate factor earli quarter eversens
launch acceler particularli larg insur contract
beyond sale insur coverag think investor look trend
drive patient physician eagernessor hesitationto adopt eversens
area interest includ whether wari implant
procedur procedur learn curv whether payment implant
explant incentiv adopt whether system featur robust
enough user target patient popul stage
launch user feedback feel product easi implant offer
signific benefit well-lik earli adopt doctor patient
import topic includ statu negoti roch updat
supplement file dose calibr timelin us
eversens xl implant trial progress develop
model chang make chang model
valuat senseon rate buy maintain pt transit
valuat method discount revenu estim
month revenu estim pt base estim
month revenu risk includ commerci launch time payor coverag
competit reimburs roch rhhbi rate distribut
agreement partnership futur data
ntm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
senseon incom revenue- gross sell research gener total oper expens incom pre-tax incom tax benefit adj net incom ep share profit incom tax net oper btig estim
preview model revenu line consensu
forecast estim anticip step-down sequenti
account season slowdown europ manag host
earn call mid-august compani opportun comment
summer trend time observ procedur weaken
consider expect summer look ahead compani
also note like see less volatil manag
fluid job push inventori facil ratabl
said expect like sourc upsid could come
brazil like continu exceed expect last quarter
compani also saw strength scandinavia franc germani
septemb compani announc transit direct distribut
model spain germani uk contempl
call look color around dynam brazil
account sale interest perspect
announc bolster size salesforc ramp dtc
advertis watch commentari regard enrol trend
 pivot trial think investor could react posit fast start
strong physician demand discuss lastli also monitor global asp
trend continu model upward bia due busi
model chang chang model time
valuat establish lab rate buy believ establish
lab share deserv multipl similar fast-grow med-tech compani
above-averag revenu growth attract gross margin less risk
around reimburs opinion target multipl reason
appli month revenu estim yield price
target add base dcf us potenti revenu get
properti fda unsatisfactori salesforc effort contract healthcar
multipl account error deterior geopolit condit
establish lab incom y/i full year good gener expens includ fv deriv expense/ incom incom incom per share analysisgross gener analysisgross gener btig
establish lab revenu ezon north west south report fx organ report fx organ report fx organ report fx organ report fx organ report fx organ zone report fx organ zone report fx changey/i organ growthzon southeastern europ asia report fx organ report fx organ report fx organ report fx organ zone report fx organ zone report fx changey/i organ growthsourc btig
preview estim revenu oper loss
lp comparison consensu look revenu
oper loss lp model assum
step-down estim previous take bit closer look
model specif assum step-down rep product
multi-system order system inflat rep metric normal
assum product metric improv model sale
recal manag expect in-lin
though dont believ risk underli busi model
base incom client call sens caution around
mix system unit vs volum may trend quarter though
share trade meaning sinc peak around earli
septemb could risk activ unit come street
estim call activ unit think earli system growth
outpac procedur growth investor disagre us
call would interest updat salesforc hire recal
compani goal add new territori compani
hire look commentari learn
nation tv advertis beta test air whether manag
intend funnel invest toward anoth nation campaign
look updat statu reimburs japan final
competit landscap remain area focu investor though
sens realli intensifi much sinc result
model chang care review product ramp
tweak estim
revenu push long-term growth estim remain
valuat neuronet rate buy pt base
month sale estim feel target multipl appropri line
averag fast-grow devic compani grow view
target multipl repres balanc view compani above-
averag near-term revenu growth attract gross margin risk around
competit risk includ competit chang reimburs
intellectu properti fda unsuccess salesforc effort contract
btig estim compani filingsnewold chang
neuronet incom etot y/i full year good expense/ incom per share reconciliationnet analysisgross ratenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmgrowth analysisgross btig estim
neuronet revenu esystem buildbegin neurostar system add forecast sale neurostar system growth/ declin neurostar system rental neurostar system system y/i build quarterli activ activ instal activ treatment session volume/avg activ neurostar y/i treatment session volum y/i treatment session growth/ declin treatment session y/i y/i y/i y/i y/i btig estim
preview electrocor earn call offer earli indic us
physician patient interest gammacor acut treatment episod
cluster headach migrain besid earli revenu key metric
like matter includ number prescript written number prescrib
physician refil rate proport revenu come cover vs self-
model total revenu consensu
forecast includ us revenu assum new patient start
patient refil quarter net price outsid
us estim intern revenu model new patient
start return patient refil net price
believ forecast achiev particularli sinc report
revenu second quarter juli commerci launch
third quarter saw meaning catalyst includ gammacor
launch next-gen gammacor sapphir launch expans us
salesforc increas number physician prescrib
gammacor accord recent manag public commentari
number prescript number prescrib increas
prescript written prescrib addit
train sale rep field almost doubl number
rep end june count prescrib found physician
finder on-line tool point increas number doctor
prescrib gammacor metric give us increment confid
ecor abil meet consensu expect
howev lack widespread reimburs coverag earli
stage launch hard estim proport gammacor
prescript convert recogn revenu back
estim prescript convert revenu roughli
prescript reportedli written quarter
us think launch catalyst like spur signific uptick
prescript
hope hear discuss gammacor posit
physician patient cgrp blocker fda approv
migrain prevent indic particularli one player eli lilli
rate reportedli offer drug free month
import topic includ progress payor coverag updat discuss
pbm earli insight refil rate clinical/regulatori pipelin
told earli feel commentari progress import
exact revenu result thousand dollar
model chang make chang model
valuat rate buy price target base
dcf assum discount rate termin ev/ebit multipl
termin multipl slightli averag ev/ebit multipl
small-microcap comp group use discount rate
fda clearanc two immedi commerci indic
still risk around execut launch abil secur
favour widespread reimburs coverag near term think
share trade quarterli report announc payor contract
risk rate price target includ reimburs commerci
execut oper adopt ramp futur capit need single-
electrocor incom gross research total oper expens incom pre-tax incom tax benefit net incom net loss attribut non-controlling comprehens incom profit incom tax net oper btig estim compani report
electrocor enu gammacor gammacor marketpati patient start price per refil deduct net price per refil gammacor net enu marketpati patient start price per refil gammacor net enu devic cost gammacor gammacor profit gammacor refil cost gammacor gammacor profit gammacor gammacor profit btig estim compani report
preview posit report august believ investor
look extend momentum revenu potenti
announc multi-unit order bookingor least progress toward larg
order share move slightli higher sinc last earn report
think investor may expect continu posit commentari order
revenu recognit
accuray forecast gross order net order
age-out guidanc estim total
revenu quarter includ product revenu servic
revenu well lp mostli line consensu
forecast gross order net order total
revenu product revenu servic revenu well
lp
model total revenu consensu
near lower end guidanc rang aray recent
trend quarterli revenu beat see consensu forecast achiev
model call gross order y/i
consensu y/i although compani longer offer
annual gross order guidanc think meet consensu remain import
investor remov guidanc metric make earn report
easier arayin past tough compani meet
revenu gross order guidanc time order instal
difficult predict precis
area interest like includ potenti impact tariff uptak
radixact system system age-out cancel medic commun
feedback recent posit prostat cancer surviv data cyberknif
statu updat china order book revenu instal
us order funnel
model chang publish forecast model y/i total
revenu growth y/i gross order growth
valuat rate neutral trade discount
mid-cap comp group use small cap due similar growth remain
neutral given lumpi order believ compani build
track record consist believ share begin see
meaning multipl expans compani must show depend
order order btig estim compani filingsnewold chang
revenu order growth btig provid price target neutral-
rate stock risk includ order volum abil convert order revenu
system fall backlog potenti dilut product delay
ntm entm eepsrevsresmedrmdnot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap bev/salescagr
accuray incom product servic total y/i total cost gross sell gener total oper incom loss incom pre-tax incom incom net incom non-controlling net incom loss dilut share sbc other- adj marginsgross net mkting oper growthnananananananananananananananananananananananasourc btig estim compani report
accuray revenu egross y/i y/i y/i y/i y/i y/i y/i product servic total btig estim compani report
preview heliu made consider progress sinc earn report
applic pon devic file fda
first clinic experi program cep announc regulatori
applic pon submit health canada compani
form commerci allianc canada
without commerci oper look addit updat
cep debut expect regulatori timelin importantli
hope hear compani plan fund need
cash launch pon devic approv would like see fund
secur end year believ hsdt share could move higher
clear plan potenti time discuss
model chang make chang model
valuat hsdt rate neutral still expect pon devic
receiv clearanc fda think time recent
fda submiss may push anticip clearanc earli neg
impact compani abil rais need capit around time
btig provid price target neutral-r stock risk includ
delay regulatori timelin regulatori clearanc interpret data
need capit commerci execut adopt ramp us reimburs
single-product compani
ntm inc ingnnot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
heliu medic incom revenue- gross profit- research total oper expens incom pre-tax incom tax benefit net incom fx translat comprehens incom profit incom tax net oper btig estim compani report
heliu medic enu pon devic pon devic marketcumul center offer pon number patient adds/cent devic devic price devic enu marketcumul center offer pon number patient adds/cent devic devic price devic enu pon devic devic pon devic btig estim compani report
preview onvo model revenu lp vs
street lp compani provid neither quarterli
annual guidanc look favor upon certain aspect
busi shorter contract cycl time potenti custom
migrat multi-project payment model time much
confid quarterli estim feel share valu today
aggreg opportun rather quarterli revenu result
continu feel potenti attract key catalyst move share
higher bullish expect around revenu ramp addit
expect real catalyst compani take materi step
toward program schedul calendar
model chang chang model time
valuat organovo rate buy pt base dcf
analysi believ near-term ramp occur slower
envis given chang focu toward diseas model away
toxicolog servic believ onvo long-term invest
multipl opportun market liver kidney tissu preclin
test billion use tissu drug
discoveri could lead royalti payment potenti market
therapeut tissu would lead signific upsid risk includ
restructur effort bear fruit complic sale channel buyer
will adopt new technolog futur need capit fda
expect sale ramp
onvo incom etot y/i sale oper incom incom tax expens incom share net one-tim ebitda co incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens btig estim compani report
onvo revenu eproduct servic modelnumb program per program servic project modelnumb per collabor project btig estim compani report
preview octob investor meet endologix pre-announce
revenu beat increas sale guidanc full year
top-line report way extens detail compani
revamp corpor strategi see formal earn report
catalyst share
forecast sale lp adj lp
street forecast sale lp
adj lp compani guid revenu lp
view earli octob investor event pre-announce posit
wrote follow-up note addit detail gave us
confid corpor strategi much remain proven
expect take quarter solid perform order elgx
regain credibl investor also believ investor await
guidanc approach stori
model chang recent refinanc updat model reflect
latest expect near-term share rais adjust decreas
share count forecast impact loss per share estim
valuat endologix rate buy pt base
month revenu estim multipl slower-grow
small- mid-cap med-tech peer well group faster-
grow small cap compani one elgx could becom
take time nellix trial play risk includ
salesforc attrit signific neg impact field safeti notic
product recal nellix never launch us slow significantli
europ competit turnov fda
bpsebit bpssourc btig estim compani filingsnewold chang
ntm medicalwmginot factset data btig estimatespr ptpricemarket cap bp/e ex-amort
elgx incom etot y/i sale clinic market opex acq oper incom incom tax incom net incom share net incom oper expens btig estim compani report
elgx revenu esal geographi unit y/i y/i south america mexico y/i y/i y/i product y/i clinic specialist unit y/i revenu per us rep y/i growth revenue per us rep y/i revenu per eu rep y/i growth revenue per ou rep y/i btig estim compani report
preview model revenu bit consensu estim
forecast assum step-down new accounts-per-rep reflect
summer season well previous mention chang
new account target process manag alreadi caution
result could impact said chang around account select
expect fairli straightforward print compani updat
guidanc earli august host subsequ strategi updat dont
expect surpris guidanc front us guidanc seem appropri
conserv assum sale forc expans impact
fewer account materi near-term catalyst view would
fda approv navig system perhap note fda
approv touch system late septemb
call await updat new commerci strategi includ
traction within new value-ad program curiou progress
made toward captur retail medicin opportun topic
wrap around partnership program curiou role obln
would play care process greater involv nutrit and/or
behaviour counsel manag indic see success among
account experi higher-touch
feel compani need meet consensu quarter row
re-establish investor interest confid continu believ
product feel physician patient interest investor seem
will wait see growth play rather jump even
also believ issu may may demand least
demand within patient look lose less weight may
indic label pre summer pre wed weight loss etc market
could develop physician may take sinc cant
market compani within fda label
model chang make chang model time
valuat obalon rate buy pt base
price risk competit end-us price percept safeti risk econom
downturn legal risk fail capit rais capit need may
avail
obln incom etot y/i sale oper incom incom tax expens incom share oper expens btig estim compani report
obln revenu eu total total y/i y/i sold balloons sale rep order btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
